Fauci says testing is a pillar of our pandemic response. Yeah, more like a fifth column.
The CDC is limiting the number of labs that can test for Monkeypox and insists on using only PCR tests. Is this system vulnerable to manipulation?
On July 25, a slew of congresspersons signed their names to a letter begging Biden, Walensky and Becerra to better fund STI clinics. The letter claims that STI clinics “need testing kits and other supplies and additional staff to scale up an appropriate response.” Fauci echoed the sentiment recently, claiming on CNN that testing is a “pillar” of the government’s monkeypox response.
There is good evidence that PCR tests were used to manipulate Covid case numbers1. Therefore, it’s worth taking a closer look into testing for Monkeypox.
What labs are allowed to perform the tests for Monkeypox? Conflicting messaging.
According to JAMA, testing must be done with PCR tests that are available from public health departments:
The clinical diagnosis of monkeypox must be confirmed using laboratory methods, which currently only are available at state public health departments, where screening polymerase chain reaction [PCR] is performed, and positive cases are sent to the CDC for specific clade confirmation.
According to the CDC testing should be done in LRN laboratories located throughout the US and abroad:
Diagnostic testing for orthopoxviruses (which includes monkeypox virus) is available at Laboratory Response Network (LRN) laboratories located throughout the United States and abroad. There is currently no commercially available assay to detect monkeypox virus…
According to Yahoo “News,” we’re using the same process we used to identify Covid early on:
A network of about 70 public health labs set up by the CDC has the capacity to identify orthopoxviruses, the family that includes smallpox and monkeypox. But local doctors must first get clearance from a state public health researcher, then somehow get the samples to one of the labs, the same process used in early 2020 to identify coronavirus infections.
And finally, according to the HHS, during the week of June 22, 2022 five commercial labs have started offering PCR testing:
The Department of Health and Human Services (HHS), through the Centers for Disease Control and Prevention (CDC), began shipping orthopoxvirus tests to five commercial laboratory companies, including the nation’s largest reference laboratories, to quickly increase monkeypox testing capacity and access in every community during the ongoing monkeypox outbreak. The companies include Aegis Science, Labcorp, Mayo Clinic Laboratories, Quest Diagnostics and Sonic Healthcare…2
Confused? Me too. Here’s how I understand it:
There are 67 laboratories (give or take) in the CDC’s Laboratory Response Network for Biological Threats (LRN-BT). Doctors send test samples to local health departments who send the samples to one of the LRN labs or to Aegis Science, Labcorp, Mayo Clinic Laboratories, Quest Diagnostics and Sonic Healthcare. Not sure if that’s entirely correct, but it’s probably close enough for this discussion. It begs the question why we need to limit testing to certain labs at all.
Why does the CDC limit Monkeypox testing to certain labs when there are thousands of labs in the country?
According to the CDC, Monkeypox should only be worked with in labs that have attained the bio-security level three (BSL-3) rating. The BSL-3 level…
is the standard for microbes that can cause serious or deadly diseases through inhalation – like COVID-19. While BSL-2 labs are safe enough for serious viruses like HIV and Staphylococcus aureus, BSL-3 level labs are required for potentially airborne diseases.
It seems a bit odd that Monkeypox would be limited to BSL-3 when nearly all the experts have been claiming that it is not airborne. “The virus can…spread via direct contact with the rash it causes, contact with body fluids, contact with respiratory secretions and intimate contact like sex, kissing, hugging and prolonged face-to-face contact, the CDC said” (MSN). Not one source says that it is an airborne disease (at least not yet…but wait for it...things change, eh?).
I was suspicious whether the CDC had only recently changed the level of security for Monkeypox, but it turns out that BSL-3 has been the standard level required for working with Monkeypox since at least 2007. The 5th and 6th edition of the Biosafety in Microbiological and Biomedical Laboratories handbook are pretty consistent on this guidance:
BSL-3 practices, containment equipment, and facilities are recommended for
monkeypox work in experimentally or naturally infected animals. BSL-2 facilities with BSL-3 practices are advised if other work with monkeypox virus is performed by vaccinated personnel.
https://www.hopkinsmedicine.org/hse/memos/BMBL_5th_Edition.pdf (from 2007)
BSL-3 practices, containment equipment, and facilities are recommended for monkeypox work in experimentally or naturally infected animals. BSL-2 facilities with BSL-3 practices are advised if vaccinated personnel perform laboratory work with monkeypox virus.
6th edition https://www.cdc.gov/labs/pdf/SF__19_308133-A_BMBL6_00-BOOK-WEB-final-3.pdf (from 2018)
Although the CDC is requiring testing to be done in LRN labs, which I presume are all BSL-3 level labs, the Biosafety in Microbiological and Biomedical Laboratories handbook allows for Monkeypox testing to be done in BSL-2 facilities, so long as the workers are smallpox vaccinated and they follow BSL-3 level protocols.
To what end is the CDC limiting Monkeypox testing to certain laboratories? Could it be that testing makes big money for Big Pharma? Just do an internet search for “who pays for Covid PCR tests” and you’ll see. PCR testing is a gold mine!
If we let only a limited number of labs test, and if those labs have ties to big pharma (which I’ll try to establish in a later article), they could be tempted to find MPX where there is no MPX. And not only will they make tons of money on the tests, but they can also sell their new untried monkeypox vaccines to the government.
I wouldn’t mind PCR testing so much, but there’s no need to insist on limiting ourselves to that kind of test. There are different ways to identify Monkeypox. So why is the CDC insisting that all testing be done with PCR tests?
How is MPX tested, and how has it been tested in the past?
It may surprise you to know that early on in the Monkeypox pandemic, two months ago, the CDC listed a comparison of confirmed cases and probable cases in the US and Africa. There were only “probable” cases in Africa but hundreds of “confirmed” cases in America. How is that possible when MPX has been endemic in Africa for nearly 50 years?
It’s all about definitions. A probable case is identified in the following way:
immunohistochemical or electron microscopy testing methods OR Demonstration of detectable levels of anti-orthopoxvirus IgM antibody during the period of 4–56 days after rash onset https://emergency.cdc.gov/han/2022/han00468.asp
And a confirmed case is identified by:
Demonstration of the presence of Monkeypox virus DNA by polymerase chain reaction testing or Next-Generation sequencing of a clinical specimen OR Isolation of Monkeypox virus in culture from a clinical specimen.
Evidently, if we are to beleive the CDC, Africa is incapable of doing culture-based testing. How condescending and racist can the CDC be?
I’m going out on a limb here because I’m not a microbiologist, but it seems to me that most labs in the world would be able to identify Monkeypox through culture-based testing.
However, the CDC says:
Culture-based testing for monkeypox virus should not be performed as a routine diagnostic procedure at clinical or diagnostic laboratories. These methods should only be performed by staff who are vaccinated against smallpox and in laboratories with validated protocols and BSL-3 containment facilities.
Since we’ve already established that it is allowable for BSL-2 level labs to work on Monkeypox as long as they follow certain practices, it is my contention that the CDC should not limit testing to PCR tests in BSL-3 level labs. We need that transparency.
Considering the abuses of PCR testing that we all witnessed during Covid, I think we all need to be aware of what’s going on with Monkeypox testing.
The CDC should allow testing in BSL-2 labs.
Upcoming Post: Are the labs trustworthy and where do the PCR tests come from?
In my next post, I hope to examine the trustworthiness of the five commercial labs and the LRN labs. The Mayo Clinic has already proven itself unreliable because of what it did with Hydroxichloroquin. In 2017 Mayo Clinic said that HCQ had only 5 side effects. By 2021, they were saying it has over 60 side effects. Please scroll to the end of my article “Hey Inslee, answer these questions and I might take your stupid shot” for more details. It’ll turn your stomach.
In February of this year, the Wuhan Institute of Virology created a fragment of the Monkeypox virus in order to develop a PCR test for Monkeypox. See my article Don’t cover your eyes for more details on this. Is the CDC using the test that is made in China? How many of the Covid tests were made in China? And why is that a big deal?
If you have any info on these topics, please forward to me. Stay vigilent. Don’t let the corporate drug cartel do the same thing they did to us with Covid.
https://cormandrostenreview.com/report/ Technical analysis of the Covid PCR tests back in December 2020.
This expansion to commercial laboratories reflects the latest, most significant increase in capacity and accessibility, building on the capacities already available within the public health Laboratory Response Network (LRN). CDC, in collaboration with the Food and Drug Administration (FDA), the Centers for Medicare & Medicaid Services, and the HHS Office of the Assistant Secretary for Preparedness and Response has also been expanding the capacity in the LRN. CDC has worked with the LRN to augment the number of public health laboratories that can perform the test to over 67 laboratories across 48 states and the number of weekly tests available within the LRN to over 8,000 tests per week